The biochemical aftermath of anti-amyloid immunotherapy

Table 2 Neuropathology of study subjects

Case ID	Aβ42 load (%)	Plaque clear-ance	Brain weight (g)	Total WMR score	Total plaque score	Plaque density	Total NFT score	Cerad NP	Braak stage	Total CAA score
NDC
1	-	-	950	n/a	6.0	zero	2.0	not AD	I	n/a
2	-	-	1275	0	7.6	sparse	3.0	not AD	II	2
3	-	-	1385	0	1.0	zero	1.0	not AD	I	0
4	-	-	1260	4	6.8	moderate	4.3	possible AD	III	3
5	-	-	1190	0	12.5	sparse	6.4	not AD	III	5
AD
6	-	-	1100	0	13.5	moderate	8.8	probable AD	IV	4
7	-	-	1145	0	13	frequent	13	definite AD	V	5
8	-	-	1055	n/a	13.25	frequent	8.75	definite AD	V	4
9	-	-	765	9	12.5	frequent	14.5	definite AD	VI	1
10	-	-	960	0	12.25	frequent	12	definite AD	V	0
11	-	-	970	10	13.25	frequent	15	definite AD	VI	10
Immunized AD*
12	4.68	+	n/a	n/a	n/a	n/a	n/a	n/a	VI	n/a
13	3.32	++	1120	n/a	n/a	n/a	n/a	n/a	VI	n/a
14	0.05	+++	1200	n/a	n/a	n/a	n/a	n/a	VI	n/a
15	2.71	++	n/a	n/a	n/a	n/a	n/a	n/a	VI	n/a
16	2.99	+	n/a	n/a	n/a	n/a	n/a	n/a	VI	n/a
19	n/a	n/a	1208	n/a	n/a	n/a	n/a	n/a	III	n/a
20	n/a	n/a	1162	n/a	n/a	n/a	n/a	n/a	IV	n/a
Immunized non-ADD*
21 PSP	0.75	0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
22 HS	n/a	n/a	1280	n/a	n/a	n/a	n/a	n/a	n/a	n/a

NDC, non-demented controls; AD, Alzheimer's disease; non-ADD, non-Alzheimer's disease dementias; PSP, progressive supranuclear palsy; HS, hippocampal sclerosis; WMR, white matter rarefaction; NFT, neurofibrillary tangle; NP, neuritic plaque; CAA, cerebral amyloid angiopathy; n/a, not available. Plaque clearance designations correspond to 0, none; +, little evidence or active process; ++, moderate/patchy; +++, complete.
*Aβ42 load and Braak stage for USSM cases taken from Holmes, et al [29], Boche, et al [30] and Boche, et al [35].

ISSN: 1750-1326